MCRB
Seres Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.56 / 10
Netural
Money flow analysis registers 7.65/10, indicating robust fund inflows despite a negative overall trend in block and medium-size flows. This healthy cash entry may support price stabilization. Analyst coverage is minimal (one opinion) but uniformly Strong Buy, aligning with the positive sentiment in fund flows; however, the scarcity of analyst views limits conviction. Together, the data present a neutral-to-positive bias from the flow and sentiment side, contrasting with the weak technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-09-24
InstitutionCanaccord Genuity
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for MCRB?
- MCRB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.56/10 (Netural).
